Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
18
References
4
Citations
NaN
KQI